Voclosporin

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 158 publications

Recent advances in immunosuppressive therapy for lupus nephritis.

Recent advances in immunosuppressive therapy for lupus nephritis.

Journal: Immunological medicine

Published: January 07, 2026

Refractory Lupus Nephritis in a Woman With Systemic Lupus Erythematosus on Immunosuppressive Therapy: A Case Report.

Refractory Lupus Nephritis in a Woman With Systemic Lupus Erythematosus on Immunosuppressive Therapy: A Case Report.

Journal: Cureus

Published: November 07, 2025

Safety assessment of voclosporin: a real-world disproportionality analysis of the FAERS database.

Safety assessment of voclosporin: a real-world disproportionality analysis of the FAERS database.

Journal: Immunopharmacology and immunotoxicology

Published: October 16, 2025

Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents.

Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents.

Journal: International journal of molecular sciences

Published: October 07, 2025

Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS (Voclosporin in Real Life Setting Study) experience.

Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS (Voclosporin in Real Life Setting Study) experience.

Journal: Rheumatology (Oxford, England)

Published: September 13, 2025

Response: Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients? Reply Letter to Capuano et al. (Letter to the Editor: Voclosporin in Late Onset Lupus Nephritis with Anti-PLA2R Antibodies).

Response: Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients? Reply Letter to Capuano et al. (Letter to the Editor: Voclosporin in Late Onset Lupus Nephritis with Anti-PLA2R Antibodies).

Journal: Seminars in arthritis and rheumatism

Published: September 10, 2025

Refractory Lupus Podocytopathy: The Role of Repeat Biopsy and Rituximab.

Refractory Lupus Podocytopathy: The Role of Repeat Biopsy and Rituximab.

Journal: Cureus

Published: September 08, 2025

Efficacy and safety of Belimumab, Rituximab and Voclosporin in the treatment of lupus nephritis based on registered clinical trials: A systematic review and network meta-analysis.

Efficacy and safety of Belimumab, Rituximab and Voclosporin in the treatment of lupus nephritis based on registered clinical trials: A systematic review and network meta-analysis.

Journal: Lupus

Published: September 05, 2025

Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 - 2024).

Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 - 2024).

Journal: International journal of clinical pharmacology and therapeutics

Published: September 01, 2025

"Voclosporin in late onset lupus nephritis with anti-PLA2R antibodies".

"Voclosporin in late onset lupus nephritis with anti-PLA2R antibodies".

Journal: Seminars in arthritis and rheumatism

Published: August 11, 2025

Efficacy and safety of calcineurin inhibitor therapy in lupus nephritis: a systematic review and network meta-analysis.

Efficacy and safety of calcineurin inhibitor therapy in lupus nephritis: a systematic review and network meta-analysis.

Journal: Frontiers in immunology

Published: July 21, 2025

Precision Editing of Cyclophilin A Generates Cyclosporine and Voclosporin Resistant Cellular Therapies.

Precision Editing of Cyclophilin A Generates Cyclosporine and Voclosporin Resistant Cellular Therapies.

Journal: bioRxiv : the preprint server for biology

Published: July 14, 2025

Showing 1-12 of 158

Last Updated: 02/24/2026